York biotech firm sees revenues rise 25% to £1.5 million
Year-on-year revenue has risen by 25 per cent ay the York-based Aptamer Group.
Read the full articleYou might also wanna read
UK medicines revenue clawback rockets to 26.5% putting Life Sciences Vision at risk, says ABPI
Next year manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government (26.5% of sales), u
India’s lifesciences sector sees momentum build in innovation: BCG -HealthKois report
Private equity and venture capital investment in pharma rose 2.1x in five years to $ 731 million for the year ended March 2026, and biotech
Syngenis banks $4M pre-float to power AI-driven biotech platform
Perth biotech Syngenis Labs has banked an oversubscribed $4M pre-IPO raise to expand its AI-powered RNA platform and strengthen domestic gen
UK set to demand a third of pharmaceutical company revenue in second half of 2025
The government is proposing to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies'
British Business Bank invests £25m in Alchemab Therapeutics, its largest direct investment in a life sciences company
British Business Bank invests £25m in Alchemab Therapeutics, its largest direct investment in a life sciences company Simon Cottam Thu, 07/0
Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a
Comments
Sign in to join the conversation.
No comments yet. Be the first.